Atria Investments Inc Boosts Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Atria Investments Inc boosted its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 6.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 905 shares of the biotechnology company’s stock after buying an additional 56 shares during the period. Atria Investments Inc’s holdings in United Therapeutics were worth $319,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Newbridge Financial Services Group Inc. bought a new position in shares of United Therapeutics during the fourth quarter valued at $25,000. Brooklyn Investment Group bought a new stake in United Therapeutics during the 3rd quarter valued at about $33,000. MassMutual Private Wealth & Trust FSB raised its holdings in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after buying an additional 58 shares during the last quarter. Jones Financial Companies Lllp raised its holdings in United Therapeutics by 678.9% in the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock worth $104,000 after buying an additional 258 shares during the last quarter. Finally, SBI Securities Co. Ltd. bought a new position in shares of United Therapeutics in the fourth quarter worth approximately $131,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on UTHR shares. UBS Group raised their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. HC Wainwright reissued a “buy” rating and issued a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. Finally, StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $388.25.

United Therapeutics Stock Performance

UTHR stock opened at $322.94 on Tuesday. The company has a market cap of $14.50 billion, a price-to-earnings ratio of 14.18, a P/E/G ratio of 0.97 and a beta of 0.64. The business’s 50-day moving average is $349.12 and its two-hundred day moving average is $358.27. United Therapeutics Co. has a fifty-two week low of $221.53 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter in the prior year, the firm earned $4.36 EPS. Equities analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Insider Buying and Selling at United Therapeutics

In other news, Director Louis W. Sullivan sold 26,209 shares of the company’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total value of $9,781,722.98. Following the completion of the sale, the director now directly owns 5,051 shares in the company, valued at $1,885,134.22. This represents a 83.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $371.05, for a total value of $3,710,500.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $956,195.85. This represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 116,464 shares of company stock valued at $42,396,244. Insiders own 11.90% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.